Published Date: 13/01/2010
Category: Drug Delivery & Devices
This comprehensive 164-page analysis of this fast-growing sector with market projections and extensive company, product and research evaluation of all major vaccine areas.
Key areas addressed by this new January 2010 report...
Companies developing DNA Vaccines
AlphaVax,Bavarian Nordic, BioVex, Crucell, CytoPulse Sciences Inc, GenVec, GeoVax, GlobeImmune, Ichor Medical Systems, Inovio Biomedical Corporation, Oxford BioMedica,Oxford-Emergent Biosolutions, Consortium, Profectus BioSciences, Sanofi Pasteur, Transgene, Vaxin Inc, Viralytics, VIRxSYS
Companies developing immune potentiators
Adjuvantix, Akela Pharma (previously Nventa Biopharmaceuticals Corp), Antigenics,CureVac, Cytos Biotechnology, Dynavax, Eisai/Sanofi Pasteur, GlaxoSmithKline, Immutep, Juvaris Biotherapeutics, Novartis, OM Pharma, Pfizer (Coley Pharmaceuticals), Vaxart, VaxInnate
Companies developing adjuvant delivery systems
Antigenics, CSL Ltd, Cytos Biotechnology,GSK, LigoCyte Pharmaceuticals, Lipoxen,Mymetics Corp, Novartis, Novavax,Oncothyreon /Merck KGaA, PDS Biotechnology, Pevion Biotech, Select Vaccines, Statens Serum Institut, TechnoVax
Companies developing novel vaccine delivery platforms
Advaxis, AEterna Zentaris, Alba Therapeutics, Altea Therapeutics, Bioject, Celldex Therapeutics, CrossJect Medical Technology, Emergent Biosolutions,Eurocine Vaccines, Injex, Intercell, LigoCyte Pharmaceuticals, MedImmune (AstraZeneca), Mucosis BV, NanoBio, NanoPass Technologies, Nanotherapeutics, NasVax, Sanofi pasteur/Becton Dickinson, Valeritas, Variation Biotechnologies, Vaxart (formerly West Coast Biologicals), Vaxin, VaxInnate/3M
The vibrant field of vaccine research will continue to grow and evolve over the next few years and to generate ever increasing revenues as new vaccines reach the market.
Unbeatable coverage and analysis of this high growth market sector...
The advances made in immunology over the past two decades, in conjunction with the growing acceptance of the importance of preventive medicine, have given the field of vaccine research a new lease of life. Vaccines for difficult infectious disease targets, such as Neisseria meningitidis Group B and malaria, may become a reality over the next five to ten years. However, for other difficult and important targets such as HIV and cancer the wait for a vaccine may be longer and will rely on the use of new technologies, including plasmid DNA, adjuvants and delivery systems that are currently in the early stages of development.
Vaccines are attracting significant research attention
The increasing use of novel technologies is reflected in the fact that almost half of the current pipeline of prophylactic vaccines against infectious diseases are in preclinical or Phase I trials. These vaccine candidates have largely been developed by smaller companies emerging from academia, such as Vical, Novavax, Acambis, Coley Pharmaceuticals, Crucell and Intercell, and represent future licensing and acquisition targets. Most of the pharma companies with the highest stakes in the vaccines market – sanofi-aventis, Pfizer, Merck & Co, GlaxoSmithKline and Novartis – have extensive pipelines of vaccine candidates in development based on acquired technology and will be vigilant for the opportunities offered by up-coming companies with promising new platform technologies.
Prophylactic vaccines: A high growth market
Our forecasts indicate that the prophylactic infectious disease vaccine market (excluding pandemic H1N1 influenza vaccines) will grow from US$21.4 billion in 2009 to US$36.4 billion in 2015, representing a compound average growth rate (CAGR 2009-2015) of 8%. This growth relies on the approval of vaccines for a number of infectious conditions for which no vaccine is currently available, such as Neisseria meningitidis Group B meningococcal disease.
Influenza: long term impact
The current influenza pandemic has also given the vaccine market sector an enormous boost in terms of revenue over the next few years, as well as future investment. Our forecasts indicate that pandemic H1N1 influenza vaccines will generate US$4.8 billion in 2009 with growth in 2010-11 and sales of these vaccines for a subsequent two year period. This pandemic H1N1 influenza vaccine forecast is subject to a number of uncertainties surrounding the ongoing extent of the pandemic and the response of individual governments to it. Increased funding for new vaccines and their manufacturing methods will change the face of the influenza vaccine market as a whole and increase the number of doses available. However, due to the large investments in expanding manufacturing capacity made by the largest pharma companies over the past few years, these changes to the overall market are likely to be realised over the next two decades rather than in the next few years.
Cancer Vaccines – when will they deliver on their promise?
In contrast to the prophylactic vaccine pipeline, the pipeline of therapeutic cancer vaccines has a higher proportion of vaccines in late-stage trials. These late-stage products utilise technologies that have not been proven successful to date and have been in development for many years; a relatively high risk of failure remains. However, the knowledge gained from human trials with cancer vaccines has informed, and will continue to inform, the development of the next generation of candidate vaccines that use new technologies to generate improved immune responses and, therefore, clinical responses in cancer patients. We forecast a total therapeutic vaccine market of US$3.7 billion in 2015. These figures are dependent on the approval of Dendreon’s Provenge in 2010, which could open up the cancer market to a new therapeutic class known as active cellular immunotherapeutics.